文献速递中医内科中药与中成药合理使用

大黄牡丹汤治疗重症急性胰腺炎:基于网络药理与实验验证的氧化应激及MAPK通路机制

Therapeutic potential of Dahuang Mudan Decoction for severe acute pancreatitis: targeting oxidative stress and MAPK pathways through network pharmacology and experimental verification1.
PubMed 文献 · J Ethnopharmacol · 2025-12-29

该研究结合网络药理学、转录组测序与小鼠体内验证,探讨大黄牡丹汤(DHMDD)治疗重症急性胰腺炎(SAP)的分子机制。结果显示DHMDD及其核心成分大黄酸通过增强腺泡细胞Nrf2/HO-1抗氧化轴、抑制巨噬细胞MAPK促炎信号发挥双重保护作用,为临床应用提供了科学依据。

要点

  • 大黄牡丹汤可减轻SAP小鼠胰腺与肺损伤,降低炎症与凋亡。
  • 核心成分大黄酸模拟DHMDD效应,是關鍵物质基础。
  • 机制涉及激活腺泡细胞Nrf2/HO-1并抑制巨噬细胞MAPK通路。

核心结论

  • 大黄牡丹汤通过增强腺泡细胞Nrf2/HO-1抗氧化轴和抑制巨噬细胞MAPK促炎信号双通路治疗SAP,核心成分大黄酸介导上述效应。

研究设计与样本

  • 研究采用网络药理学、转录组测序与小鼠体内实验验证相结合的方法,先以雨蛙素诱导MAP小鼠确定最佳剂量,再用L-精氨酸诱导SAP模型进行机制研究。

主要发现

  • 在MAP小鼠中,各剂量DHMDD均减轻胰腺损伤并降低血清脂肪酶和淀粉酶,高剂量效果最佳。
  • 在SAP小鼠中,高剂量DHMDD显著减轻胰腺和肺组织病理损伤,减少腺泡细胞凋亡,降低炎症细胞浸润和细胞因子水平。
  • LC-MS鉴定DHMDD血吸收入血成分,网络药理学基于此预测366个SAP潜在治疗靶点,与转录组差异基因交集分析确认核心调控靶点。
  • KEGG富集分析提示炎症相关MAPK信号和氧化应激相关通路参与,转录组数据予以佐证。
  • 动物实验验证大黄酸在两个测试剂量下减轻SAP诱导的胰腺和肺损伤,减少凋亡和炎症,效果与DHMDD类似。

临床怎么用

  • 大黄牡丹汤及其核心成分大黄酸可作为SAP潜在治疗选择,机制涉及抗氧化与抗炎双通路。
  • 大黄酸可作为靶向药物开发的候选成分,为DHMDD临床治疗SAP提供物质基础依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Acute pancreatitis (AP) is an inflammatory disease caused by the premature activation of digestive enzymes, leading to pancreatic self-digestion. In about 20 % of cases, AP progresses to severe acute pancreatitis (SAP), a life-threatening condition with high mortality. In traditional Chinese medicine (TCM), SAP corresponds to the "Yangming Fu-organ Excess Syndrome," attributed to internal damp-heat and toxin accumulation, Fu-organ qi obstruction, and blood stasis. Dahuang Mudan Decoction (DHMDD), a classic formula from Zhang Zhongjing's Eastern Han Dynasty text Synopsis of the Golden Chamber, can clear heat, detoxify, promote digestion, activate blood circulation, and resolve stasis. Despite its proven clinical efficacy, the molecular mechanisms of DHMDD remain unclear and require further investigation. AIM OF THE STUDY: This research sought to systematically elucidate the molecular mechanisms of DHMDD against SAP using an integrated approach that combines network pharmacology, transcriptome sequencing, and in vivo animal validation, and to identify its core bioactive components. MATERIALS AND METHODS: To investigate the effect of DHMDD on severe acute pancreatitis (SAP), we first established a mild-to-moderate acute pancreatitis (MAP) mouse model via caerulein injection to determine the optimal therapeutic dose of DHMDD. Subsequently, an SAP model was induced with L-arginine for mechanistic studies. We used liquid chromatography-mass spectrometry (LC-MS) to identify the blood-absorbed components of DHMDD in SAP mice. The potential mechanisms of DHMDD against SAP were screened by integrating network pharmacology (based on the absorbed components) with transcriptomic sequencing; intersection analysis was performed to identify core targets and pathways. Core bioactive components were pinpointed through molecular docking. Finally, in vivo validation was conducted: SAP mice were treated with DHMDD and its key component (rhein) at different doses to verify the therapeutic effects and regulation of the core pathways, thereby confirming DHMDD's anti-SAP efficacy and material basis. RESULTS: Initial experiments showed that all doses of DHMDD alleviated pancreatic injury and lowered serum lipase and amylase levels in MAP mice, with high-dose showing the greatest benefit. In SAP mice, high-dose DHMDD also markedly reduced pathological injury in pancreatic and lung tissues, decreased acinar cell apoptosis, and lowered inflammatory cell infiltration and cytokine levels. LC-MS identified the blood-absorbed components of DHMDD, and subsequent network pharmacology analysis, based on these components, pinpointed 366 potential therapeutic targets for SAP. Intersection analysis of these targets with transcriptomic differentially expressed genes (DEGs) from pancreatic tissues confirmed the core regulatory targets. KEGG enrichment analysis highlighted the involvement of inflammation-related MAPK signaling and oxidative stress-related pathways, a finding corroborated by transcriptomic data. Notably, animal experiments validated that the core bioactive component, rhein, at two tested doses, alleviated SAP-induced pancreatic and lung injury, reduced apoptosis and inflammation, mirroring the effects of DHMDD. Both DHMDD and rhein significantly suppressed MAPK pathway activation in macrophages while enhancing the antioxidant response in acinar cells via activation of the Nrf2/HO-1 signaling cascade. CONCLUSION: We have elucidated a dual mechanism for DHMDD in SAP: enhancing the Nrf2/HO-1 antioxidant axis in acinar cells and suppressing pro-inflammatory MAPK signaling in macrophages. The identified core component, rhein, mediates these effects, confirming its role as the key material basis. This work provides a scientific foundation for DHMDD's clinical use and positions rhein as a candidate for targeted drug development against SAP.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Duan L, Luo Y, Shang C, et al. Therapeutic potential of Dahuang Mudan Decoction for severe acute pancreatitis: targeting oxidative stress and MAPK pathways through network pharmacology and experimental verification1. J Ethnopharmacol. 2025. PMID: 41475625. doi:10.1016/j.jep.2025.121116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。